UPDATE: Click here to order samples for your practice.
Jump to section:
*Post-hoc analysis. Xalatan (latanoprost) 0.005% mean diurnal IOP reduction of 7.8 mmHg.
‡Pooled results from the APOLLO and LUNAR studies: ocular adverse reactions occurring in ≥2% of study eyes.3,7
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Phase 3, randomized, multicenter, double-masked, parallel-group study in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)
Phase 2, dose-ranging study vs Xalatan (latanoprost) 0.005% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)
A single-arm, multicenter, open-label, long-term study in Japanese patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)